Background: Over the past 10 years, the first-line chemotherapy in metastatic gastric cancer is considered to be extended (mGC) survival time of patients with the standard treatment. New evidence suggests that , compared with best supportive care program , second-line treatment of salvage chemotherapy may have a survival advantage . But after an unsuccessful second-line chemotherapy treatment results are poor, remission rate was 0-5% , and prolong survival in patients with no evidence of Therefore, in order to achieve the purpose of survival benefit , are urgently needed new and more effective treatment. Past studies have shown that inhibition of vascular endothelial growth factor (VEGF) targeted antiangiogenic strategies can be effectively used for lung, breast , kidney , liver and colon cancer treatment. However, in improving mGC overall survival (OS) or progression-free survival (PFS) , the antitumor activity of this strategy is still relatively scarce evidence . Currently in VEGF receptor (VEGFR) inhibitor therapy mGC patient research results are more scarce. Bevacizumab treatment of gastric phase III clinical trials (AVAGAST) subgroup analysis data show that low levels of plasma VEGF-A compared to non- Asian patients , VEGF-A levels may be higher in patients with VEGF inhibitors bevacizumab through anti improved OS, the results show that the APA for screening patients for Nicole to bring some benefit . And a recent randomized, placebo-controlled study gained more positive results. The study showed that compared with the placebo group compared with patients receiving ramucirumab patients treated mGC significantly longer PFS and OS . Preclinical studies showed that the new APA VEGFR inhibitor imatinib (YN968D1) can be used as a potential cancer therapeutic agents . With Vatalanib as APA imatinib is a small molecule VEGFR tyrosine kinase inhibitor , but its affinity for the Vatalanib or sorafenib 10 times . Phase I clinical trials showed that the drug on China mGC patients with anti- tumor activity. Thus, according to pre-clinical studies and Phase I clinical trial data , continued to carry out the controlled clinical phase II randomized, double-blind, placebo-controlled trial .
Background:
ReplyDeleteOver the past 10 years, the first-line chemotherapy in metastatic gastric cancer is considered to be extended (mGC) survival time of patients with the standard treatment. New evidence suggests that , compared with best supportive care program , second-line treatment of salvage chemotherapy may have a survival advantage . But after an unsuccessful second-line chemotherapy treatment results are poor, remission rate was 0-5% , and prolong survival in patients with no evidence of Therefore, in order to achieve the purpose of survival benefit , are urgently needed new and more effective treatment. Past studies have shown that inhibition of vascular endothelial growth factor (VEGF) targeted antiangiogenic strategies can be effectively used for lung, breast , kidney , liver and colon cancer treatment. However, in improving mGC overall survival (OS) or progression-free survival (PFS) , the antitumor activity of this strategy is still relatively scarce evidence .
Currently in VEGF receptor (VEGFR) inhibitor therapy mGC patient research results are more scarce. Bevacizumab treatment of gastric phase III clinical trials (AVAGAST) subgroup analysis data show that low levels of plasma VEGF-A compared to non- Asian patients , VEGF-A levels may be higher in patients with VEGF inhibitors bevacizumab through anti improved OS, the results show that the APA for screening patients for Nicole to bring some benefit . And a recent randomized, placebo-controlled study gained more positive results. The study showed that compared with the placebo group compared with patients receiving ramucirumab patients treated mGC significantly longer PFS and OS .
Preclinical studies showed that the new APA VEGFR inhibitor imatinib (YN968D1) can be used as a potential cancer therapeutic agents . With Vatalanib as APA imatinib is a small molecule VEGFR tyrosine kinase inhibitor , but its affinity for the Vatalanib or sorafenib 10 times .
Phase I clinical trials showed that the drug on China mGC patients with anti- tumor activity. Thus, according to pre-clinical studies and Phase I clinical trial data , continued to carry out the controlled clinical phase II randomized, double-blind, placebo-controlled trial .
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
GW 5074
AZ 628
ZM 336372
SP600125
CC-401 HCl
JNK-IN-8
AS 602801
SB 203580
SB 202190
Doramapimod